Plexus Ventures
Plexus
We help companies identify, evaluate, and negotiate in-licensing opportunities to expand their growth potential and geographic presence.
We are global experts in pharmaceutical divestments, working with companies to target buyers, generate competition for assets, and maximize proceeds.
We help firms identify potential product and company acquisitions, develop deal structures, and negotiate definitive agreements.
We advise companies in developing an out-licensing strategy and guide them in maximizing the value of their compounds, products, and technologies.
GLOBAL PRESENCE world

+1-310-584-7480

info@plexusventures.com
RECENT NEWS
  • August 23, 2011 Labormed Pharma Retains Plexus Ventures for Product Divestment Support
  • July 22, 2011 AstraZeneca Engages Plexus Ventures for Global Divestments
  • June 24, 2011 Plexus Ventures Successfully Concludes Product Divestment Assignment
  • June 6, 2011 Plexus Ventures to Support Reckitt Benckiser in Portfolio Divestment
PharmaTimes World News
  • February 7, 2012Pharma sales flat but GSK pleased with R&D progress
  • February 7, 2012Orexigen agrees trial design for obesity drug with FDA
  • February 7, 2012Pharma fears it is not up to demands of 'value challenge' - EIU
  • February 7, 2012Merck & Co to file first-in-class insomnia drug with FDA in 2012
  • February 6, 2012Novartis gets fresh EU approval for 'under-appreciated' Galvus
Home | About | Services | Track Record | News Room | Contact | Japanese Japanese Language
  • Overview
  • Our Approach
  • Our History
  • Our Team
  • Our Offices
  • Overview
  • In-Licensing
  • Out-Licensing
  • Acquisitions
  • Divestments
  • Overview
  • Case Studies
  • Client List
  • Press Releases
  • Articles & Presentations
  • Media Inquiries